Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avant BrandsTSX:AVNT 31 Debt-to-Equity is 0.60 as of May. 2026, which is 200% above its 10-year median of 0.20. GuruFocus rates TSX:AVNT with a GF Score™ of 31/100 and a GF Value™ of C$0.95 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 811 Drug Manufacturers companies, Avant Brands ranks worse than 74.85% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Avant Brands's Debt-to-Equity or its related term are showing as below:
TSX:AVNT'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.06 Med: 0.2 Max: 0.69
Current: 0.6
During the past 13 years, the highest Debt-to-Equity Ratio of Avant Brands was 0.69. The lowest was -0.06. And the median was 0.20.
TSX:AVNT's Debt-to-Equity is ranked worse than 74.85% of 811
companies
in the Drug Manufacturers industry
Industry Median: 0.28
vs TSX:AVNT: 0.60
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Avant Brands Debt-to-Equity Related Terms
Avant Brands Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Avant Brands's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Avant Brands's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avant Brands Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Avant Brands's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Avant Brands's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avant Brands (TSX:AVNT) has a Debt-to-Equity of 0.60 as of May. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Avant Brands and its competitors. This is 200% above median its historical median of 0.20. According to the industry distribution chart, Avant Brands ranks #607 out of 811 companies in the Drug Manufacturers industry, placing it in the top 74.8%.
Is Avant Brands' Debt-to-Equity too high?
Avant Brands' current Debt-to-Equity of 0.60 is 200% above median its 10-year median of 0.20. The Drug Manufacturers industry median Debt-to-Equity is 0.28. Avant Brands' value of 0.60 is 114.3% above this industry median. Based on the distribution chart, Avant Brands ranks #607 out of 811 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Avant Brands has a GF Score™ of 31/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Avant Brands' Debt-to-Equity compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Avant Brands ranks #607 out of 811 companies for Debt-to-Equity. This places Avant Brands in the lower half of its industry. The industry median Debt-to-Equity is 0.28. Avant Brands' value of 0.60 is 114.3% above this benchmark. While the company's 10-year median is 0.20 vs. the industry median of 0.28, Avant Brands has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.28, based on 811 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Avant Brands's current Debt-to-Equity of 0.60 is 114.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Avant Brands and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avant Brands's current Debt-to-Equity is 0.60, which is 200% above median its own 10-year median of 0.20. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avant Brands stock overvalued right now?
Based on GuruFocus' analysis, Avant Brands (TSX:AVNT) is currently considered Possible Value Trap. The stock's GF Value™ is C$0.95, compared to a current price of C$0.58 — trading 38.9% below its estimated fair value. The current Debt-to-Equity is 0.60, which is 200% above median its 10-year median of 0.20 and 114.3% above the Drug Manufacturers industry median of 0.28. Avant Brands' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Avant Brands (TSX:AVNT), the current Debt-to-Equity is 0.60 as of May. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Avant Brands (TSX:AVNT) Overvalued in 2026?
Based on GuruFocus' analysis, Avant Brands stock appears to be undervalued.
The current stock price of C$0.58 is trading 38.9% below its estimated GF Value™ of C$0.95.
GuruFocus considers Avant Brands to be Possible Value Trap.
Key valuation signals for TSX:AVNT:
Debt-to-Equity: 0.60 (200% above median its 10-year median of 0.20)
GF Value™: C$0.95 vs. price of C$0.58 (38.9% below fair value)
Industry Position: 114.3% above the Drug Manufacturers median (#607 of 811)
No single metric tells the full story. See the TSX:AVNT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Avant Brands Inc operating in the cannabis industry, engages in the cultivation, production, marketing, and sale of cannabis products. Its product portfolio mainly consists of dried cannabis flower and related cannabis products, with the company managing the entire value chain from cultivation and harvesting to processing, packaging, and distribution, generating revenue upon delivery of products to customers. It operates in Canada.
31GF Score
Get the complete analysis for TSX:AVNT
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSX:AVNT has been successfully added to your 
